The drug is clemastine (brand name Tavist).
If it works in people, how long will it be available as a cheap over the counter drug, I wonder.
It has been proposed as an additional therapy for schizophrenia (not a replacement for antipsychotics) because of its effects on myelin.
Based on the literature reviewed here, there are WM deficits that correlate with treatment resistance in schizophrenia. While other mechanisms of pharmacoresistance are still possible for any particular patient, if we consider WM as a target for therapy, there are options that are in development for human use. In fact, myelin enhancing strategies have been under investigation in human subjects for many years as effective treatments for multiple sclerosis are sought. Thus, repurposing and investigating these approved therapeutics currently in use for other medical conditions for treatment resistant patients is a reasonable approach. More specifically, putative myelinenhancing therapies would be potential candidates for large-scale clinical trials in schizophrenia. These include myelin-enhancing agents such as n-3 PUFA, minocycline , clemastine, polyphenols and potential neuro/myeloreparative agents such as sulfasalazine, nano-curcumin, stem cell enhancing therapies such as Gli-1 inhibitors, immunodmodulators such as fingolimod, olexosime and retinoid receptor activators such as pioglitazone.